Skip to main content

Market Overview

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
  • AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines.
  • The collaboration will leverage AbCellera's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.
  • Under the agreement terms, Moderna will have the right to develop and commercialize antibodies resulting from the collaboration. 
  • AbCellera will receive research payments and is eligible to receive from Moderna downstream clinical and commercial milestone payments and royalties on net sales of products.
  • Recently, AbCellera acquired TetraGenetics Inc, a platform to generate recombinant human ion channels and other transmembrane proteins. Deal terms were not disclosed.
  • Price Action: ABCL stock is up 9.28% at $19.31, and MRNA stock is down 0.1% at $427 during the premarket session on the last check Wednesday.

Related Articles (MRNA + ABCL)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Health Care Contracts Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at